| Title |
Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2012
|
| DOI | 10.1002/14651858.cd010179 |
| Pubmed ID | |
| Authors |
Andrew H Travers, Stephen J Milan, Arthur P Jones, Carlos A Camargo Jr, Brian H Rowe |
| Abstract |
Inhaled beta-agonist therapy is central to the management of acute asthma. This review evaluates the benefit of an additional use of intravenous beta(2)-agonist agents. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 9% |
| Kuwait | 1 | 9% |
| Argentina | 1 | 9% |
| Ecuador | 1 | 9% |
| United Kingdom | 1 | 9% |
| Unknown | 6 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Scientists | 2 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Denmark | 1 | <1% |
| Unknown | 217 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 34 | 15% |
| Researcher | 23 | 10% |
| Other | 17 | 8% |
| Student > Bachelor | 15 | 7% |
| Student > Postgraduate | 13 | 6% |
| Other | 35 | 16% |
| Unknown | 83 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 80 | 36% |
| Nursing and Health Professions | 19 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Social Sciences | 7 | 3% |
| Psychology | 4 | 2% |
| Other | 10 | 5% |
| Unknown | 90 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2018.
All research outputs
#1,282,074
of 23,661,575 outputs
Outputs from Cochrane database of systematic reviews
#2,932
of 12,747 outputs
Outputs of similar age
#11,168
of 283,344 outputs
Outputs of similar age from Cochrane database of systematic reviews
#39
of 199 outputs
Altmetric has tracked 23,661,575 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,747 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.4. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,344 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 199 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.